Therapeutic Approaches in Modulating the Inflammatory and Immunological Response in Patients With Sepsis, Acute Respiratory Distress Syndrome, and Pancreatitis: An Expert Opinion Review
- PMID: 34692364
- PMCID: PMC8526068
- DOI: 10.7759/cureus.18393
Therapeutic Approaches in Modulating the Inflammatory and Immunological Response in Patients With Sepsis, Acute Respiratory Distress Syndrome, and Pancreatitis: An Expert Opinion Review
Abstract
Immunomodulation has long been an adjunct approach in treating critically ill patients with sepsis, acute respiratory distress syndrome (ARDS), and acute pancreatitis (AP). Hyperactive immune response with immunopathogenesis leads to organ dysfunction and alters the clinical outcomes in critically ill. Though the immune response in the critically ill might have been overlooked, it has gathered greater attention during this novel coronavirus disease 2019 (COVID-19) pandemic. Modulating hyperactive immune response, the cytokine storm, especially with steroids, has shown to improve the outcomes in COVID-19 patients. In this review, we find that immune response pathogenesis in critically ill patients with sepsis, ARDS, and AP is nearly similar. The use of immunomodulators such as steroids, broad-spectrum serine protease inhibitors such as ulinastatin, thymosin alpha, intravenous immunoglobulins, and therapies such as CytoSorb and therapeutic plasma exchange may help in improving the clinical outcomes in these conditions. As the experience of the majority of physicians in using such therapeutics may be limited, we provide our expert comments regarding immunomodulation to optimize outcomes in patients with sepsis/septic shock, ARDS, and AP.
Keywords: ards; covid-19; immunomodulators; sepsis; steroid; ulinastatin.
Copyright © 2021, Mehta et al.
Conflict of interest statement
The authors have declared financial relationships, which are detailed in the next section.
Figures
References
-
- Immune response in critically ill patients. Surbatovic M, Vojvodic D, Khan W. https://doi.org/10.1155/2018/9524315. Mediators Inflamm. 2018;2018:9524315. - PMC - PubMed
-
- Assessment of immune organ dysfunction in critical illness: utility of innate immune response markers. Pfortmueller CA, Meisel C, Fux M, Schefold JC. https://doi.org/10.1186/s40635-017-0163-0. Intensive Care Med Exp. 2017;5:49. - PMC - PubMed
-
- The immune system in critical illness. Marshall JC, Charbonney E, Gonzalez PD. Clin Chest Med. 2008;29:605-16, vii. - PubMed
-
- Cytokine signaling--regulation of the immune response in normal and critically ill states. Oberholzer A, Oberholzer C, Moldawer LL. Crit Care Med. 2000;28:0–12. - PubMed
-
- Inflammation and innate immune function in critical illness. Muszynski JA, Thakkar R, Hall MW. Curr Opin Pediatr. 2016;28:267–273. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials